Read: Senators raise alarm over Delta's AI pricing plan
Why it matters: Sens. Ruben Gallego (D-Ariz.), Mark Warner (D-Va.) and Richard Blumenthal (D-Conn.) wrote that Delta's personalized "current and planned individualized pricing practices" would present data privacy concerns and "likely mean" fare price rises "up to each individual consumer's personal 'pain point'" at a time when many families were struggling.
Zoom in: "Consumers have no way of knowing what data and personal information your company and Fetcherr plan to collect or how the AI algorithm will be trained," wrote the senators, in reference to the Israeli company that developed a Generative Pricing Engine tool.
"Prices could be dictated not by supply and demand, but by individual need," they added.
"While Delta has stated that the airline will 'maintain strict safeguards to ensure compliance with federal law,' your company has not shared what those safeguards are or how you plan to protect American families against pricing discrimination in the evolving AI landscape."
What they're saying:"There is no fare product Delta has ever used, is testing, or plans to use that targets customers with individualized offers based on personal information or otherwise," a Delta spokesperson said in an emailed statement late Monday.
"A variety of market forces drive the dynamic pricing model that's been used in the global industry for decades, with new tech simply streamlining this process. Delta always complies with regulations around pricing and disclosures."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Pfizer's (PFE) Breakthrough Medicines Power its Dividend Stability
Pfizer Inc. (NYSE:PFE) is included among the . A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. The American multinational biotech firm developed a form of santonin used to treat intestinal worms, which gained rapid popularity thanks to its effectiveness. One of its founders, Erhart, drew on his background in candy-making to add an almond-toffee flavor, making the medicine easier to take. Around the same time, the company also started producing citric acid, a key ingredient in popular beverages like Coca-Cola. This product eventually became a core part of Pfizer's business and played a major role in its growth over the following decades. Pfizer Inc. (NYSE:PFE) has struggled in recent years, with its stock falling by over 28% in the past decade. Despite this underperformance, the future looks more promising due to a solid lineup of drugs in development. Many of the concerns surrounding the company seem to be already priced into its lower share value. Recently, Pfizer's forward price-to-earnings ratio was 8.49, which is well below its five-year average of 10.2. In addition to its innovation, Pfizer Inc. (NYSE:PFE) has always remained committed to its shareholder obligations. In the most recent quarter, it returned $2.4 billion to investors through dividends. Moreover, it has raised its payouts for 15 consecutive years. The company pays a quarterly dividend of $0.43 per share and has a dividend yield of 7.08%, as of July 28. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
20 minutes ago
- The Hill
Bipartisan Senate price transparency bill can fix US health care
In the aftermath of Republicans' divisive reconciliation bill, Congress has the opportunity to come together and pass bipartisan legislation to address one of the nation's biggest problems: The broken health care system. Approximately 100 million Americans have health care debt, and one-quarter of insured families avoid care each year due to unknown costs. The Patients Deserve Price Tags Act, recently introduced by Sens. Roger Marshall (R-Kan.) and John Hickenlooper (D-Colo.), can reverse runaway health care costs that are placing a tremendous burden on American families by empowering them to compare and save. Since 2000, hospital prices have increased by 257 percent, which explains why the growth rate in health insurance premiums has outstripped workers' earnings by a ratio of almost 3 to 1 over this timeframe. The Marshall-Hickenlooper bill gives employers and patients the upfront price information they need to protect themselves from overcharges and choose affordable care. It requires the publication of actual prices, including discounted cash and negotiated insurance rates, not estimates, throughout the health care system. And it requires insurers to give patients an advanced explanation of benefits —a breakdown of costs, including their out-of-pocket responsibility — before care is delivered. I joined a letter signed by 40 leading health economists calling on senators to co-sponsor and quickly pass this crucial legislation. Economists understand actual prices are essential to functioning marketplaces that generate fair-market costs. Under the opaque status quo, consumers are essentially required to pay for care with the equivalent of a blank check, giving hospitals and health insurers tremendous market power to overcharge and profiteer. Hidden prices result in wide cost variations for the same care, a sign of market failure. Recent research I conducted for Rice University's Baker Center reveals that mean outpatient hospital prices in Houston vary by nearly 200 percent for the same insurer. A recent study in Health Affairs Scholar shows that colonoscopy rates can vary by seven times for those with the same health coverage. Price transparency corrects this information asymmetry between consumers and providers, putting downward and convergent pressure on prices. It fosters competition and returns excessive health industry profits to patients, businesses, unions, school districts and workers where they belong. Redirecting funds from the health care industrial complex back to the private economy can create an enormous economic stimulus. Employers and employees especially stand to benefit. The average employer-sponsored family health insurance plan now costs $24,000 per year, with workers bearing the majority of the cost through premium deductions and lower wages. One analysis found that about the same amount of employee compensation growth since 2000 has gone to premium costs as to paychecks. Transparency empowers employers to steer workers to high-value care, reducing premium costs and increasing take-home pay. The Marshall-Hickenlooper bill also gives employers access to their claims data and reveals the contractual relationships of their health plan administrators, allowing them to remedy overbilling and spread pricing. My research suggests that lowering annual premiums by just $1,373 per employee can boost the profitability of retail businesses by an average of 12.4 percent. You don't need to be an economist to understand that upfront prices are needed to avoid overcharges and shop for affordable care and coverage. But economists can speak to the significant impact of price transparency on business earnings, worker paychecks and economic dynamism. Actual prices, as required by the Marshall-Hickenlooper bill, can restore affordability, accountability and trust to American health care. That's something people of all political persuasions can support.
Axios
20 minutes ago
- Axios
Scoop: Senate Dems launching last-ditch bid to block Trump tariffs
Senate Democrats on Wednesday will mount a last-ditch effort to block President Trump's tariffs from taking full effect at the end of this week, Axios has learned. Why it matters: Democrats, who argue Trump's tariffs could add $2,400 to the average American household expenses, are making signs of economic angst a centerpiece of their 2026 midterm messaging. Sen. Jeanne Shaheen (D-N.H.) on Wednesday evening will ask lawmakers to unanimously pass a bill affirming that the tariffs can't be authorized under the International Emergency Economic Powers Act, Axios has learned. That's the law the administration is citing as giving it the authority to impose the levies. Friday is the date when tariffs rise for dozens of countries, as threatened by Trump in letters earlier this month. Many are lower than the rates he first imposed in April, though some are higher. Driving the news: It will take just one lawmaker to block Shaheen's move, and Republicans will almost certainly do so. But it gives Democrats the opportunity to get Republicans on the record in support of the tariff hikes. Shaheen's move comes one day before a federal appellate court hears arguments on whether to overturn a lower-court ruling that the IEEPA tariffs were illegal. Zoom out: The unanimous consent request is part of broader anti-tariff push that Democrats will hold on the Senate floor on Wednesday evening, according to people familiar with the matter. Shaheen will lead a half dozen Democratic senators in highlighting the impact the duties will have on working families. "And now, on Friday, the Administration is planning to make the goods businesses and families need 10, or 30 or even 40 percent more expensive overnight," Shaheen will say, according to remarks shared with Axios.
